CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (4732) Cancer Therapeutics (1137)
Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market. The company has advanced the frontier of antibody discovery by creating well-char...Show all
Company (Alive / Active)
Phone: +45 4526 5050
Pederstrupvej 93
Ballerup, DK-2750
Denmark
| Total Funding | Date of Last Funding | |
|---|---|---|
| Symphogen | $364.2M | Nov 30, 2017 |
| Humanetics Corporation | $0.6M | Oct 10, 2017 |
| PharmAthene | $61.2M | Mar 14, 2005 |
| See all 19 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Humanized pan-her antibody compositions | May 02, 2013 | Dec 27, 2016 | Patent |
| Anti-her3 antibodies and compositions | Oct 31, 2011 | Dec 22, 2015 | Patent |
| Method for manufacturing recombinant polyclonal proteins | Dec 19, 2008 | Oct 20, 2015 | Patent |
| Pan-her antibody composition | Nov 01, 2011 | Oct 13, 2015 | Patent |
| Methods using recombinant anti-epidermal growth factor receptor antibody compositions | Aug 27, 2009 | Mar 04, 2014 | Patent |
Download PDF